CJC-1295 is not „banned” in the sense of being an illegal street drug. However, it is banned in professional sports under global anti-doping regulations. And it has never received approval as an actual medicine from any major drug regulator. These are three related, yet distinct, facts that often get conflated. As legal and regulatory status can change and vary significantly by country, this article reflects the most current information available. It also clearly notes where the picture is still unresolved or actively changing.
CJC-1295 jest zazwyczaj zakazany w sporcie, ponieważ jest to syntetyczny hormon peptydowy, który może zwiększać poziom hormonu wzrostu (GH) w organizmie. Zwiększony poziom GH może prowadzić do zwiększonego wzrostu mięśni, lepszej regeneracji i zmniejszonej tkanki tłuszczowej, co daje zawodnikom nieuczciwą przewagę. Z tego powodu substancje takie jak CJC-1295 są ujęte w listy zakazanych substancji przez wiele organizacji sportowych i agencji antydopingowych, takich jak Światowa Agencja Antydopingowa (WADA).
CJC-1295 is explicitly listed as a prohibited substance on the World Anti-Doping Agency (WADA) Prohibited List. It is categorised under S2, which covers peptide hormones, growth factors, and related substances. Specifically, it falls under the subsection of Growth Hormone Releasing Hormone (GHRH) analogues, alongside related compounds such as sermorelin and tesamoren [1]. This prohibition applies both in-competition and out-of-competition. There is no „off-season” period where a tested athlete can use it and remain compliant with regulations.
The rationale for this classification stems from the fundamental mechanism of CJC-1295. WADA prohibits substances that meet specific criteria: potential for performance enhancement, potential health risks, or conflict with the broader spirit of fair competition. A compound designed to permanently elevate growth hormone and IGF-1 – which has been demonstrated for CJC-1295 in human studies – fits squarely within the type of substance these frameworks were built for [2].
Outside of sport, „forbidden” is a less precise word to use. CJC-1295 is not classified as a controlled substance under drug classification regulations in the United States. A more accurate regulatory description is that it has never completed the clinical trial and approval process required for the FDA or any comparable regulator to authorise it as a marketed drug. This is a different legal status than being listed as an illegal drug.
Is CJC-1295 legal in Europe?
The legal status of CJC-1295 varies significantly across European countries. This is an area where the regulatory landscape can change, so readers should verify current legislation with their own national health authority, rather than rely on this summary alone.
In several European countries – including Germany, France, the Netherlands, Sweden, Norway, Denmark and Spain – it has been reported that CJC-1295 requires a valid prescription for legal access. This is typically done through a licensed physician operating within that country's drug regulations, and it is not available over-the-counter or without medical involvement [3].
Specifically in the UK, regulatory guidance has described CJC-1295 as not having current marketing authorisation from the MHRA. This means that its unauthorised supply for human use falls outside of the Human Medicines Regulations 2012. UK Anti-Doping (UKAD) also applies the same WADA prohibited status described above to any athlete under its testing programmes [4].
Across the European Union more broadly, the general pattern holds. CJC-1295 has not received marketing authorisation from the European Medicines Agency (EMA) for any indication. This means it does not have the same legal status as an approved prescription medicine in EU member states – even in countries where a doctor may still prescribe it through other regulatory pathways, such as for compounding arrangements.
As regulations differ by country and are continually evolving, this article does not offer country-specific purchasing advice. Any individual with questions regarding their situation should consult their national drug regulator or a licensed healthcare professional directly.
Is CJC-1295 approved by the FDA?
CJC-1295 is not approved by the FDA for any medical use. There is no completed New Drug Application or equivalent approval for it in the United States.
The history of its development helps explain why. Early-stage human studies in the mid-2000s indicated it could raise growth hormone and IGF-1 levels [5]. However, a subsequent Phase 2 clinical trial specifically testing it in patients with HIV-associated visceral obesity was not completed. The compound's development as a finished pharmaceutical product appears to have been discontinued rather than taken through the full approval process [6].
Separate from full drug approval, the FDA also maintains regulations concerning which „bulk drug substances” compounding pharmacies may prepare for patient-specific prescriptions, under Section 503A of federal law. This classification for CJC-1295 compounding was reportedly subject to change during 2026. Some sources describe regulatory changes and an ongoing pending review process.
As this particular drug classification is actively under review at the time of writing, and accounts of the situation vary slightly between different sources, this article does not state a single definitive status for the drug here. Readers needing a precise, current answer should check the FDA's own published bulk drug substance lists on fda.gov directly. This is the authoritative source, and the situation may have changed since this article was written.
It can be stated with certainty: CJC-1295 has never been a finished medicinal product approved by the FDA. It is not legally sold as a dietary supplement. And it remains, at the very least, a research compound from the perspective of federal drug approval.
How long is CJC-1295 detectable in urine?
Anti-doping laboratories have developed analytical methods capable of detecting CJC-1295 in urine at very low concentrations. This is an important background for understanding detection windows, although the exact number of days for which an individual would test positive depends on factors such as dose and individual metabolism – details that cannot be reduced to a single universal number.
A peer-reviewed analytical chemistry study has developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. This method could detect CJC-1295 and several related GHRH analogues in spiked urine at concentrations at or below the World Anti-Doping Agency's (WADA) required limit of detection of 1 nanogram per millilitre. The researchers built this method on a detailed analysis of the compound's in vitro metabolites [7].
This type of sensitivity means that the detection technology for CJC-1295 is truly advanced and continues to improve. Separate anti-doping research in veterinary medicine has developed immuno-PCR-based assays capable of detecting CJC-1295 protein conjugates in horse plasma, down to 0.8 picograms per millilitre. This illustrates how low a concentration modern testing can identify [8].
It is worth noting, however, that the reviewed literature consulted for this article does not specify a single, universal „detection window” measured in days for CJC-1295 in humans. The actual elimination time depends on several factors: the dose administered, whether a long-acting form bound with DAC or a shorter-acting form without DAC was used, and individual differences in metabolism. This means that any specific number of days presented elsewhere as a fixed rule should be treated with some caution, rather than as an exact, universally applicable figure.
Limitations of current evidence
The clearest and most stable fact across all the sources reviewed here is the WADA ban on CJC-1295. This is well-documented and consistent.
The FDA's formulation classification, however, is presented differently in various sources at the time of writing. This truly reflects an unsettled and actively reviewed regulatory situation, rather than a stable, agreed-upon fact. This article deliberately avoids stating one definitive number when primary sources disagree or when an official review is still ongoing.
Similarly, the European legal status at a national level can differ and change. The detectability window numbers for anti-doping testing also depend on variables not fully captured by a single number.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as legal advice. The legal regulations surrounding research compounds vary by country and change over time, and the information here reflects the most current available understanding at the time of writing. CJC-1295 is not approved by the FDA or the European Medicines Agency for any medical use. Its status under anti-doping regulations, including by the World Anti-Doping Agency (WADA), and its prescription or re-prescription status in any given country should be independently verified with the appropriate regulatory body prior to use. This content does not constitute legal or medical advice. Any individual with questions regarding the legal status of CJC-1295 in their jurisdiction should consult with qualified legal counsel.
References
[1] World Anti-Doping Agency. (2025). The forbidden list. https://www.wada-ama.org/en/prohibited-list
[2] Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogues. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
peptide.law. (28 February 2026). The legality of CJC-1295 varies significantly by country and is often dependent on its intended use. In many places, it is classified as a research chemical and is not approved for human consumption. Therefore, its sale and possession for personal use may be illegal. As of 2026, there is no universal legal status for CJC-1295 across 158 countries. Here's a general overview of its typical legal standing: * **Research Chemical:** In most Western countries (including the USA, UK, Canada, and EU member states), CJC-1295 is typically sold for research purposes only. This means it is not approved by regulatory bodies like the FDA (US), MHRA (UK), or EMA (EU) for medical use. Possession or sale for human consumption can lead to legal penalties. * **Prohibited Substances:** In some countries, particularly those with strict drug control laws, CJC-1295 may be explicitly listed as a prohibited substance, making its possession and sale illegal regardless of intent. * **Grey Areas:** Some countries may have less defined regulations, creating grey areas where the substance might be available but its legality is uncertain or enforced inconsistently. * **Athletic Bans:** It's important to note that CJC-1295 is banned by most major sports organisations, including the World Anti-Doping Agency (WADA). Athletes caught using it face significant sanctions. **To determine the specific legal status in any given country, you would need to consult the laws and regulations of that particular nation.** These laws can change, so it's crucial to seek up-to-date information from reliable legal or governmental sources within the country in question. The information for 158 countries in 2026 would require a comprehensive legal review specific to each jurisdiction.. https://peptide.law/peptides/cjc-1295
[4] Bolt Pharmacy. (2026, 21 May). CJC 1295, ipamorelin and retatrutide: UK safety and legal guide. https://www.boltpharmacy.co.uk/guide/cjc-1295-ipamorelin-retatrutide
[5] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[6] National Centre for Biotechnology Information. (2026). PubChem Compound Summary for CID 91971820, CJC-1295 [Clinical trial data: NCT00267527 and EudraCT 2005-003797-25]. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/91971820
[7] Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogues. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
Timms, M., Ganio, K., & Steel, R. (2019). A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Testing and Analysis, 11(8), 1248–1257. https://doi.org/10.1002/dta.2599